Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 3Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Melanoma 1Lymphoma 1Locally Advanced Breast Cancer (LABC) 1Liver Neoplasms 1Hodgkin Disease 1Esophageal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma 1Breast Neoplasms, Male 1

Interventions

pembrolizumab 7Cyclophosphamide 7Surveys and Questionnaires 4Filgrastim 4aldesleukin 3Radiotherapy 3Peripheral Blood Stem Cell Transplantation 3Paclitaxel 3Nivolumab 3Methods 3Flow Cytometry 3Early Intervention, Educational 3valspodar 2sargramostim 2fludarabine 2atezolizumab 2Therapeutics 2Stem Cell Factor 2Sirolimus 2Methylprednisolone 2Melphalan 2Ipilimumab 2Interleukin-2 2Immunologic Techniques 2Exercise 2Etoposide 2Epoetin Alfa 2Educational Status 2Drug Therapy 2Data Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × advexin × Breast × Clear all
NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

MultiVir, Inc.

Phase 2 Unknown
40 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡